Cardiovascular Systems, Inc. (NASDAQ:CSII) Given Consensus Rating of “Hold” by Analysts

Shares of Cardiovascular Systems, Inc. (NASDAQ:CSIIGet Rating) have earned an average recommendation of “Hold” from the seven ratings firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $35.00.

A number of equities research analysts have issued reports on the stock. StockNews.com began coverage on shares of Cardiovascular Systems in a report on Thursday, March 31st. They issued a “hold” rating on the stock. Bank of America started coverage on shares of Cardiovascular Systems in a report on Wednesday, March 2nd. They issued an “underperform” rating for the company.

Shares of Cardiovascular Systems stock opened at $13.74 on Friday. The firm has a market cap of $560.39 million, a PE ratio of -16.36 and a beta of 0.92. Cardiovascular Systems has a 12-month low of $13.46 and a 12-month high of $44.57. The company has a quick ratio of 4.58, a current ratio of 5.28 and a debt-to-equity ratio of 0.08. The company’s fifty day simple moving average is $17.24 and its two-hundred day simple moving average is $18.79.

Cardiovascular Systems (NASDAQ:CSIIGet Rating) last announced its quarterly earnings results on Wednesday, May 4th. The medical device company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.03. The business had revenue of $56.22 million for the quarter, compared to analyst estimates of $57.38 million. Cardiovascular Systems had a negative net margin of 13.29% and a negative return on equity of 12.43%. The company’s revenue was down 11.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.15) EPS. As a group, sell-side analysts expect that Cardiovascular Systems will post -0.91 earnings per share for the current fiscal year.

In other news, CFO Jeffrey S. Points bought 3,000 shares of Cardiovascular Systems stock in a transaction dated Friday, May 20th. The shares were acquired at an average price of $14.50 per share, with a total value of $43,500.00. Following the completion of the purchase, the chief financial officer now owns 109,312 shares in the company, valued at approximately $1,585,024. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.00% of the stock is owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its holdings in shares of Cardiovascular Systems by 1.1% during the 1st quarter. BlackRock Inc. now owns 7,087,402 shares of the medical device company’s stock valued at $160,176,000 after purchasing an additional 80,138 shares in the last quarter. Champlain Investment Partners LLC increased its stake in Cardiovascular Systems by 5.0% during the fourth quarter. Champlain Investment Partners LLC now owns 3,488,625 shares of the medical device company’s stock worth $65,516,000 after purchasing an additional 167,105 shares during the period. State Street Corp increased its stake in Cardiovascular Systems by 12.6% during the fourth quarter. State Street Corp now owns 1,747,278 shares of the medical device company’s stock worth $32,814,000 after purchasing an additional 195,818 shares during the period. Neuberger Berman Group LLC grew its position in shares of Cardiovascular Systems by 8.8% during the first quarter. Neuberger Berman Group LLC now owns 806,497 shares of the medical device company’s stock worth $18,215,000 after buying an additional 65,351 shares in the last quarter. Finally, Invesco Ltd. grew its position in shares of Cardiovascular Systems by 60.3% during the third quarter. Invesco Ltd. now owns 657,596 shares of the medical device company’s stock worth $21,589,000 after buying an additional 247,303 shares in the last quarter. Institutional investors and hedge funds own 91.24% of the company’s stock.

About Cardiovascular Systems (Get Rating)

Cardiovascular Systems, Inc, a medical device company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products, which are catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products.

Featured Articles

Analyst Recommendations for Cardiovascular Systems (NASDAQ:CSII)

Want More Great Investing Ideas?

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.